- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01238367
A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543
February 9, 2017 updated by: Novo Nordisk A/S
Multi-centre, Open-label, Non-randomised Single Dose Trial Investigating the Pharmacokinetics of N8 in Japanese Subjects With Haemophilia A
This trial is conducted in Japan.
The aim of this clinical trial is to investigate the pharmacokinetics (the effect of the investigated drug on the body) and safety of turoctocog alfa (recombinant factor VIII (N8)) in Japanese subjects with haemophilia A.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Itabashi-ku, Tokyo, Japan, 173 8606
- Novo Nordisk Investigational Site
-
Kashihara-shi, Nara, Japan, 634 8522
- Novo Nordisk Investigational Site
-
Maebashi-shi, Gunma, Japan, 371-8511
- Novo Nordisk Investigational Site
-
Shinjuku-ku, Tokyo, Japan, 160 0023
- Novo Nordisk Investigational Site
-
Shizuoka-shi, Shizuoka, Japan, 4208660
- Novo Nordisk Investigational Site
-
Suginami-ku, Tokyo, Japan, 1670035
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 66 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Japanese subjects who have completed NN7008-3543
- No detectable inhibitors to factor VIII
Exclusion Criteria:
- Congenital or acquired coagulation disorders other than haemophilia A
- Planned surgery during the trial period
- Receipt of any investigational drug other than recombinant factor VIII (N8) within 30 days of trial product administration
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: recombinant factor VIII (N8)
|
Subjects will receive recombinant factor VIII (N8) at a dose of 50 +/- 5 IU/kg body weight.
Intravenous administration as a single bolus injection.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incremental recovery
Time Frame: Infusion, 30 minutes
|
Infusion, 30 minutes
|
Area under the curve
Time Frame: Infusion, 30 minutes
|
Infusion, 30 minutes
|
In vivo t1/2
Time Frame: Infusion, 30 minutes
|
Infusion, 30 minutes
|
Total clearance (CL)
Time Frame: Infusion, 30 minutes
|
Infusion, 30 minutes
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximal concentration
Time Frame: at 15 minutes
|
at 15 minutes
|
Area under the curve
Time Frame: from time zero to last
|
from time zero to last
|
Number of adverse events
Time Frame: from day -1 to day 3 (end of trial)
|
from day -1 to day 3 (end of trial)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2010
Primary Completion (Actual)
October 1, 2011
Study Completion (Actual)
October 1, 2011
Study Registration Dates
First Submitted
November 9, 2010
First Submitted That Met QC Criteria
November 9, 2010
First Posted (Estimate)
November 10, 2010
Study Record Updates
Last Update Posted (Actual)
February 10, 2017
Last Update Submitted That Met QC Criteria
February 9, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN7008-3600
- U1111-1117-1286 (Other Identifier: WHO)
- JapicCTI-101346 (Other Identifier: JAPIC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Bleeding Disorder
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Congenital FXIII DeficiencyUnited States, Israel, United Kingdom
-
Novo Nordisk A/SCompletedObservational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII DeficiencyCongenital Bleeding Disorder | Congenital FVII DeficiencyJapan
-
Novo Nordisk A/SEnrolling by invitationCongenital Bleeding Disorder | Congenital FXIII DeficiencyJapan
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Congenital FXIII DeficiencySpain, United States, Canada, Italy, United Kingdom, Hungary
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Congenital FXIII DeficiencyUnited Kingdom, Israel, United States
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding Disorder | Congenital FXIII DeficiencyUnited Kingdom
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding Disorder | Congenital FXIII DeficiencyUnited Kingdom
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding Disorder | Congenital FXIII DeficiencyUnited Kingdom
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Congenital FXIII DeficiencyUnited States, Israel, Austria, Spain, Switzerland, Germany, Canada, France, United Kingdom, Italy, Finland
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding DisorderUnited States
Clinical Trials on turoctocog alfa
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia AJapan
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia AItaly, Sweden, Netherlands, Austria, Spain, United States, Switzerland, Germany, France, Hungary, Greece, Slovenia, Czechia, Slovakia, Poland
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia AUnited States, Spain, Germany, Switzerland, Serbia, Taiwan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Japan, Denmark, Hungary, Israel, Turkey, Russian Federation, Former Serbia and Montenegro
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia AUnited Kingdom, Malaysia
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia AMexico
-
Novo Nordisk A/STerminatedHaemophilia AAustria, Serbia, Bulgaria, United Kingdom, Germany, France, Turkey
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia AIndia
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia AAustria, Spain, United States, Germany, Serbia, Taiwan, Bulgaria
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia AUnited States, Denmark, Austria, Spain, Japan, Brazil, Algeria, Lithuania, Portugal, Russian Federation, Serbia, Turkey, Greece, Hong Kong, Puerto Rico, Hungary, China, Poland